HeartBeam, Inc.
corporate_fare Company Profile
HeartBeam, Inc. (NASDAQ:BEAT) is a publicly traded company in the Life Sciences sector. Wiseek has independently scored 29 items for BEAT at importance 7 or higher on its 1–10 market-impact scale. Its most recent item scored 7 or higher is dated 2026-09-28, rated 7/10. Across its 20 most recent items scored 7 or higher, the top rating is 9/10, with 8 rated 8 or above. Recent SEC coverage for BEAT spans 8-K, SCHEDULE 13D/A, 10-Q, 8-K/A.
Recent high-impact activity:
- HeartBeam Completes ALIGN-ACS Enrollment, Eyes FDA Pivotal Study
- HeartBeam Launches $25M At-The-Market Offering Amid Going Concern Warning
- HeartBeam Launches $25M At-The-Market Offering Amid Going Concern
- Strome Entities Dump 1.39M HeartBeam Shares at Steep Losses
- HeartBeam Q2 2026: $5.0M Net Loss, Going Concern Warning, and $11.5M Raise
Financial Snapshot
Short Interest & Short Volume
5.13 days to coverFINRA reported short interest of 2,124,373 shares in BEAT as of the September 15, 2026 settlement, a 9.4% increase from the prior period — about 5.1 days to cover at its recent average daily volume. On October 2, 2026, 44.2% of BEAT volume reported to FINRA trade-reporting facilities was marked short.
Daily short sale volume covers trades reported to FINRA trade-reporting facilities and is not the same as short interest (bi-monthly reported positions). Source: FINRA — FINRA is the owner and source of this short interest and short sale volume data; it may not be redistributed.
Dilution Risk
Low riskFiling-implied dilution signals for BEAT, detected from its recent SEC filings · based on capital-structure filings through 2026-08-14.
Finalized Public Offering · Significant Capital Raise
A filing-implied signal, not a realized share count. How Wiseek tracks dilution →